{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:22:09Z","timestamp":1777728129957,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify potential drug interactions (DIs) between pangenotypic direct-acting antivirals (pDAAs) and concomitant cardiovascular (CV) therapies in patients with chronic hepatitis C (CHC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was carried out. Patients \u226518 years of age diagnosed with CHC and treated with pDAAs during 2017 were included. Information was collected on concomitant CV therapies and potential DIs [ www.hep-druginteractions.org ]. The pDAAs analyzed were sofosbuvir\/velpatasvir (SOF\/VEL), glecaprevir\/pibrentasvir (GLE\/PIB) and sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX). An analysis including lipid-lowering drugs was also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 1286 patients (mean age 64.9 years, 56.6% men) were recruited. The percentages of potential DIs with CV drugs were 1.9% contraindications, 38.1% clinically significant and 2.4% weak. When lipid-lowering drugs were included, the percentages of potential DIs with CV drugs were 10.3% contraindications, 46.3% clinically significant and 3.2% weak. Potential DIs associated with each pDAA were as follows (contraindications; clinically significant; weak): SOF\/VEL (1.4%; 23.0%; 0.9%), GLE\/PIB (12.8%; 60.8%; 4.7%) and SOF\/VEL\/VOX (16.6%; 55.1%; 4.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately on third of patients with CHC are concomitantly treated with CV drugs. SOF\/VEL may have fewer DIs with CV drugs than other pDAAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060520964659","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T05:55:10Z","timestamp":1603864510000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection"],"prefix":"10.1177","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-293X","authenticated-orcid":false,"given":"Antoni","family":"Sicras-Mainar","sequence":"first","affiliation":[{"name":"Scientific Management, Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Morillo-Verdugo","sequence":"additional","affiliation":[{"name":"Pharmacist, Specialist in Hospital Pharmacy, Hospital de Valme, AGS Sur de Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"bibr1-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2018.09.006"},{"key":"bibr2-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"bibr3-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221231"},{"key":"bibr4-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4284-9"},{"key":"bibr5-0300060520964659","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041479"},{"key":"bibr6-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00466-1"},{"key":"bibr7-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1505502"},{"key":"bibr8-0300060520964659","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S205282"},{"key":"bibr9-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13673"},{"key":"bibr10-0300060520964659","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.11.1261"},{"key":"bibr11-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13095"},{"key":"bibr12-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12763"},{"key":"bibr13-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2019.03.014"},{"key":"bibr14-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.1764"},{"key":"bibr15-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"bibr16-0300060520964659","unstructured":"World Health Organization. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD). http: \/\/www.who.int\/classifications\/atcddd\/en\/ (2003, accessed 28 September 2020)."},{"key":"bibr17-0300060520964659","unstructured":"University of Liverpool. University of Liverpool HIV & Hepatitis Pharmacology Group Drug Interaction Charts. http: \/\/www.hep-druginteractions.org\/Interactions.aspx (2020, accessed 28 September 2020)."},{"key":"bibr18-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02235.x"},{"key":"bibr19-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv396"},{"key":"bibr20-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172159"},{"key":"bibr21-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15051"},{"key":"bibr22-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1519392"},{"key":"bibr23-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27920"},{"key":"bibr24-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2017.1344102"},{"key":"bibr25-0300060520964659","first-page":"33","volume":"209","author":"Casas Arrate J","year":"2017","journal-title":"El Farmac\u00e9utico Hospitales"},{"key":"bibr26-0300060520964659","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa040"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520964659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060520964659","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520964659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:51:20Z","timestamp":1777459880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060520964659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/0300060520964659"],"URL":"https:\/\/doi.org\/10.1177\/0300060520964659","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"article-number":"0300060520964659"}}